162 related articles for article (PubMed ID: 36237138)
1. Benefits and safety of Oxymetazoline cream 1% on rosacea-associated erythema: A systematic review and analysis of clinical evidence.
Yuan X; Yin D
J Cosmet Dermatol; 2023 Jan; 22(1):103-110. PubMed ID: 36237138
[TBL] [Abstract][Full Text] [Related]
2. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
Baumann L; Goldberg DJ; Stein Gold L; Tanghetti EA; Lain E; Kaufman J; Weng E; Berk DR; Ahluwalia G
J Drugs Dermatol; 2018 Mar; 17(3):290-298. PubMed ID: 29537447
[TBL] [Abstract][Full Text] [Related]
3. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Kircik LH; DuBois J; Draelos ZD; Werschler P; Grande K; Cook-Bolden FE; Weng E; Berk DR; Ahluwalia G
J Drugs Dermatol; 2018 Jan; 17(1):97-105. PubMed ID: 29320594
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
Draelos ZD; Gold MH; Weiss RA; Baumann L; Grekin SK; Robinson DM; Kempers SE; Alvandi N; Weng E; Berk DR; Ahluwalia G
J Am Acad Dermatol; 2018 Jun; 78(6):1156-1163. PubMed ID: 29409914
[TBL] [Abstract][Full Text] [Related]
5. Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0.
Tanghetti EA; Dover JS; Goldberg DJ; Dhawan SS; Luo L; Berk DR; Ahluwalia G; Alvandi N
J Drugs Dermatol; 2018 Jun; 17(6):621-626. PubMed ID: 29879249
[TBL] [Abstract][Full Text] [Related]
6. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
Patel NU; Shukla S; Zaki J; Feldman SR
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1049-1054. PubMed ID: 28837365
[TBL] [Abstract][Full Text] [Related]
7. Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials.
Stein-Gold L; Kircik L; Draelos ZD; Werschler P; DuBois J; Lain E; Baumann L; Goldberg D; Kaufman J; Tanghetti E; Ahluwalia G; Alvandi N; Weng E; Berk D
J Drugs Dermatol; 2018 Nov; 17(11):1201-1208. PubMed ID: 30500142
[TBL] [Abstract][Full Text] [Related]
8. Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study.
Tanghetti EA; Goldberg DJ; Dover JS; Geronemus RG; Bai Z; Alvandi N; Shanler SD
Lasers Surg Med; 2021 Jan; 53(1):55-65. PubMed ID: 32378241
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea.
DuBois J; Dover JS; Jones TM; Weiss RA; Berk DR; Ahluwalia G
J Drugs Dermatol; 2018 Mar; 17(3):308-316. PubMed ID: 29537449
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis.
Liu F; Zhou Q; Wang H; Fu H; Li Y; Tao M; Luo H; Cao Y
J Cosmet Dermatol; 2023 Sep; 22(9):2408-2419. PubMed ID: 37128814
[TBL] [Abstract][Full Text] [Related]
11. Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study.
Eichenfield LF; Del Rosso JQ; Tan JKL; Hebert AA; Webster GF; Harper J; Baldwin HE; Kircik LH; Stein-Gold L; Kaoukhov A; Alvandi N
Br J Dermatol; 2019 May; 180(5):1050-1057. PubMed ID: 30500065
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
Kuang AW; DuBois J; Attar M; Ahluwalia G
J Drugs Dermatol; 2018 Feb; 17(2):213-220. PubMed ID: 29462230
[TBL] [Abstract][Full Text] [Related]
13. Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence.
Del Rosso JQ; Tanghetti E
J Clin Aesthet Dermatol; 2021 Mar; 14(3):32-37. PubMed ID: 33841614
[No Abstract] [Full Text] [Related]
14. Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Okwundu N; Cline A; Feldman SR
J Dermatolog Treat; 2021 Mar; 32(2):137-143. PubMed ID: 31294643
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Erythematotelangiectatic Rosacea With Pulsed-Dye Laser and Oxymetazoline 1.0% Cream: A Retrospective Study.
Suggs AK; Macri A; Richmond H; Munavalli G; Friedman PM
Lasers Surg Med; 2020 Jan; 52(1):38-43. PubMed ID: 31709571
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea.
Sodha P; Suggs A; Munavalli GS; Friedman PM
Lasers Surg Med; 2021 Dec; 53(10):1307-1315. PubMed ID: 34233378
[TBL] [Abstract][Full Text] [Related]
17. Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea.
Hoover RM; Erramouspe J
Ann Pharmacother; 2018 Mar; 52(3):263-267. PubMed ID: 29094614
[TBL] [Abstract][Full Text] [Related]
18. Oxymetazoline Hydrochloride 1% Cream (Rhofade) for Persistent Facial Erythema Associated with Rosacea.
Garcia C; Birch M
Am Fam Physician; 2018 Jun; 97(12):808-810. PubMed ID: 30216014
[No Abstract] [Full Text] [Related]
19. Ivermectin treatment in rosacea: How novel smartphone technology can support monitoring rosacea-associated signs and symptoms.
Schaller M; Riel S; Bashur R; Kurup N; Schnidar H; Fehrenbacher B
Dermatol Ther; 2022 Nov; 35(11):e15869. PubMed ID: 36177738
[TBL] [Abstract][Full Text] [Related]
20. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment.
Gold MH; Lebwohl M; Biesman BS; Robinson DM; Luo L; Berk DR; Ahluwalia G; Alvandi N
J Am Acad Dermatol; 2018 Sep; 79(3):e57-e59. PubMed ID: 29860043
[No Abstract] [Full Text] [Related]
[Next] [New Search]
